EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC-ND 4.0

Affinity maturation endows potent activity onto class 6 SARS-CoV-2 broadly neutralizing antibodies

Ohan Mazigi, David B Langley iD, Jake Y Henry, Deborah L Burnett iD, Meghna Sobti iD, Gregory J Walker iD, Romain Rouet, Harikrishnan Balachandran, Helen Lenthall, Jennifer Jackson iD, Stephanie Ubiparipovic, Peter Schofield und 15 weitere

Proceedings of the National Academy of Sciences · 2025

DOI: 10.1073/pnas.2417544121 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Proceedings of the National Academy of Sciences, 2025. Verfasst von Ohan Mazigi und 26 weiteren Autor:innen. Beteiligte Einrichtung: Garvan Institute of Medical Research, Sydney, NSW 2010, Australia. Hauptthemen laut MEDLINE: SARS-CoV-2, Spike Glycoprotein, Coronavirus, COVID-19, Antibodies, Viral. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 51 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: DHAC | National Health and Medical Research Council (NHMRC), Medical Research Future Fund.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

The emergence of SARS-CoV-2 variants of concern (VOCs) has greatly diminished the neutralizing activity of previously FDA-approved monoclonal antibodies (mAbs), including that of antibody cocktails and of first-generation broadly neutralizing antibodies such as S309 (Sotrovimab). In contrast, antibodies targeting cryptic conformational epitopes of the receptor binding domain (RBD) have demonstrated broad activity against emerging variants, but exert only moderate neutralizing activity, which has so far hindered clinical development. Here, we utilize in vitro display technology to identify and affinity-mature antibodies targeting the cryptic class 6 epitope, accessible only in the “up” conformation of the SARS-CoV-2 spike trimer. Increasing antibody affinity into the low picomolar range endowed potent neutralization of VOCs and protection of hACE2 mice from viral challenge. Cryoelectron microscopy and crystal structures of two affinity-matured antibodies (4C12-B12 and 4G1-C2) in complex with RBD highlighted binding modes and epitopes distal from mutational hotspots commonly overserved in VOCs, providing direct structural insights into the observed mutational resistance. Moreover, we further demonstrate that antibodies targeting the class 6 epitope, rather than being an artifact of in vitro selection, are common in the IgG1 + memory B cell repertoire of convalescent patients and can be induced in human antibody V-gene transgenic mice through immunization. Our results highlight the importance of very high (picomolar) affinity in the development of neutralizing antibodies and vaccines and suggest an affinity threshold in the provision of broad and long-lasting immunity against SARS-CoV-2.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

SARS-CoV-2Spike Glycoprotein, CoronavirusCOVID-19Antibodies, ViralAntibodies, NeutralizingAnimalsHumansMiceAntibody AffinityEpitopesAntibodies, MonoclonalBroadly Neutralizing AntibodiesCryoelectron Microscopy

Stichwörter der Autor:innen

COVIDantibodyimmunity

Substanzen

Spike Glycoprotein, CoronavirusAntibodies, ViralAntibodies, Neutralizingspike protein, SARS-CoV-2EpitopesAntibodies, MonoclonalBroadly Neutralizing Antibodies

Autor:innen und Institutionen

  • Garvan Institute of Medical Research, Sydney, NSW 2010, Australia.
  • University of New South Wales Sydney, St. Vincent's Clinical School, Faculty of Medicine, Sydney, NSW 2010, Australia.
  • University of New South Wales Sydney, School of Biomedical Sciences, Faculty of Medicine, Sydney, NSW 2052, Australia.
  • Victor Chang Cardiac Research Institute, Sydney, NSW 2010, Australia.
  • Prince of Wales Hospital, Sydney, NSW 2031, Australia.
  • Kirby Institute, University of New South Wales Sydney, Sydney, NSW 2033, Australia.

ORCID-Profile: David B Langley, Deborah L Burnett, Meghna Sobti, Gregory J Walker, Jennifer Jackson, Sebastian R Schulz, Markus Hoffmann, Stefan Pöhlmann, Jeffrey Post, Golo Ahlenstiel, William D Rawlinson, Rowena A Bull, Hans-Martin Jäck, Christopher C Goodnow, Daniel Christ

Förderung

  • DHAC | National Health and Medical Research Council (NHMRC)
  • Medical Research Future Fund

Zitieren

APA

Mazigi, O., Langley, D. B., Henry, J. Y., Burnett, D. L., Sobti, M., Walker, G. J., Rouet, R., Balachandran, H., Lenthall, H., Jackson, J., Ubiparipovic, S., Schofield, P., Brown, S. H. J., Schulz, S. R., Hoffmann, M., Pöhlmann, S., Post, J., Martinello, M., Ahlenstiel, G., …, & Christ, D. (2025). Affinity maturation endows potent activity onto class 6 SARS-CoV-2 broadly neutralizing antibodies. Proceedings of the National Academy of Sciences. https://doi.org/10.1073/pnas.2417544121

Vancouver

Mazigi O, Langley DB, Henry JY, Burnett DL, Sobti M, Walker GJ, et al. Affinity maturation endows potent activity onto class 6 SARS-CoV-2 broadly neutralizing antibodies. Proceedings of the National Academy of Sciences. 2025. doi:10.1073/pnas.2417544121

BibTeX
@article{Mazigi2025,
  author = {Mazigi, Ohan and Langley, David B and Henry, Jake Y and Burnett, Deborah L and Sobti, Meghna and Walker, Gregory J and Rouet, Romain and Balachandran, Harikrishnan and Lenthall, Helen and Jackson, Jennifer and Ubiparipovic, Stephanie and Schofield, Peter and Brown, Simon H J and Schulz, Sebastian R and Hoffmann, Markus and Pöhlmann, Stefan and Post, Jeffrey and Martinello, Marianne and Ahlenstiel, Golo and Kelleher, Anthony and Rawlinson, William D and Turville, Stuart G and Bull, Rowena A and Stewart, Alastair G and Jäck, Hans-Martin and Goodnow, Christopher C and Christ, Daniel},
  title = {Affinity maturation endows potent activity onto class 6 SARS-CoV-2 broadly neutralizing antibodies},
  journal = {Proceedings of the National Academy of Sciences},
  year = {2025},
  doi = {10.1073/pnas.2417544121}
}
Kostenlos starten →